UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 130

Sortiert nach

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

The Lancet (British edition), 2015-10, Vol.386 (10002), p.1472-1483

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting APOC3 in the Familial Chylomicronemia Syndrome

The New England journal of medicine, 2014-12, Vol.371 (23), p.2200-2206

2014

Link zum Volltext

Verfügbarkeit prüfen

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Circulation research, 2013-05, Vol.112 (11), p.1479-1490

2013

Link zum Volltext

Verfügbarkeit prüfen

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Diabetes care, 2016-08, Vol.39 (8), p.1408-1415

2016

Link zum Volltext

Verfügbarkeit prüfen

Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial

Annals of neurology, 2009-07, Vol.66 (1), p.28-38

2009

Link zum Volltext

Verfügbarkeit prüfen

A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans

Molecular therapy. Nucleic acids, 2012-11, Vol.1 (11), p.e52-e52, Article e52

2012

Link zum Volltext

Verfügbarkeit prüfen

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

European heart journal, 2020-10, Vol.41 (40), p.3936-3945

2020

Link zum Volltext

Verfügbarkeit prüfen

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

The New England journal of medicine, 2015-07, Vol.373 (5), p.438-447

2015

Link zum Volltext

Verfügbarkeit prüfen

Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Journal of clinical lipidology, 2016-05, Vol.10 (3), p.707-708

2016

Link zum Volltext

Verfügbarkeit prüfen

An Antisense Inhibitor of Apolipoprotein C-III Substantially Decreases Fasting Apolipoprotein C-III and Triglyceride Levels in LPL Deficiency

Journal of clinical lipidology, 2014-05, Vol.8 (3), p.353-354

2014

Link zum Volltext

Verfügbarkeit prüfen

Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis

Arthritis research & therapy, 2015-03, Vol.17 (1), p.80-80, Article 80

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 16993: An Antisense Inhibitor of Apolipoprotein C-III Significantly Decreases Nonesterified Fatty Acid Levels in Severe Hypertriglyceridemic Patients

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Link zum Volltext

Verfügbarkeit prüfen

AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III SIGNIFICANTLY DECREASES APOLIPOPROTEIN C-III, TRIGLYCERIDES, VERY-LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER, AND INCREASES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER IN HYPERTRIGLYCERIDEMIC PATIENTS ON A FIBRATE

Journal of the American College of Cardiology, 2014-04, Vol.63 (12), p.A1453-A1453

2014

Link zum Volltext

Verfügbarkeit prüfen

No effect on QT intervals of mipomersen, a 2′-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects

European journal of clinical pharmacology, 2016-03, Vol.72 (3), p.267-275

2016

Link zum Volltext

Verfügbarkeit prüfen

AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III LOWERS FASTING PLASMA APOLIPOPROTEIN C-III AND TRIGLYCERIDE CONCENTRATIONS IN HEALTHY VOLUNTEERS

Journal of the American College of Cardiology, 2012-03, Vol.59 (13), p.E1685-E1685

2012

Link zum Volltext

Verfügbarkeit prüfen

Antisense therapies for cardiovascular/metabolic diseases

Drug discovery today. Therapeutic strategies, 2013, Vol.10 (3), p.e165-e170

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system

The American journal of medicine, 1987-12, Vol.83 (6), p.10-14

1987

Link zum Volltext

Verfügbarkeit prüfen

Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: A controlled-release formulation of nifedipine

The American journal of medicine, 1987-12, Vol.83 (6), p.10-14

1987

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the Immediate Effects of Five β-Adrenoreceptor-Blocking Drugs with Different Ancillary Properties in Angina Pectoris

The New England journal of medicine, 1979-04, Vol.300 (14), p.750-755

1979

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of Minipress XL, a new once-a-day formulation of prazosin

The American journal of medicine, 1989-08, Vol.87 (2), p.S45-S52

1989

Link zum Volltext

Verfügbarkeit prüfen

Effect of trimazosin on serum lipid profiles in hypertensive patients

The American heart journal, 1983-11, Vol.106 (5), p.1265-1268

1983

Link zum Volltext

Verfügbarkeit prüfen

Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris

The American journal of medicine, 1980-02, Vol.68 (2), p.243-250

1980

Link zum Volltext

Verfügbarkeit prüfen

Magnetic and structural properties of rare earth transition metal carbides and nitrides

Singleton, Eric Walter

1994

Link zum Volltext
ProQuest

Postjunctional Selectivity of α-Blockade with Prazosin, Trimazosin, and UK-33,274 in Man

Journal of cardiovascular pharmacology, 1982, Vol.4 Suppl 1, p.S145-S151

1982

Link zum Volltext

Verfügbarkeit prüfen

Profile of trimazosin: An effective and safe antihypertensive agent

The American heart journal, 1983-11, Vol.106 (5), p.1269-1281

1983

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 130

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(108)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

Targeting APOC3 in the Familial Chylomicronemia Syndrome

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial

A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

An Antisense Inhibitor of Apolipoprotein C-III Substantially Decreases Fasting Apolipoprotein C-III and Triglyceride Levels in LPL Deficiency

Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis

Abstract 16993: An Antisense Inhibitor of Apolipoprotein C-III Significantly Decreases Nonesterified Fatty Acid Levels in Severe Hypertriglyceridemic Patients

AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III SIGNIFICANTLY DECREASES APOLIPOPROTEIN C-III, TRIGLYCERIDES, VERY-LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER, AND INCREASES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER IN HYPERTRIGLYCERIDEMIC PATIENTS ON A FIBRATE

No effect on QT intervals of mipomersen, a 2′-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects

AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III LOWERS FASTING PLASMA APOLIPOPROTEIN C-III AND TRIGLYCERIDE CONCENTRATIONS IN HEALTHY VOLUNTEERS

Antisense therapies for cardiovascular/metabolic diseases

Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system

Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: A controlled-release formulation of nifedipine

Comparison of the Immediate Effects of Five β-Adrenoreceptor-Blocking Drugs with Different Ancillary Properties in Angina Pectoris

Efficacy and safety of Minipress XL, a new once-a-day formulation of prazosin

Effect of trimazosin on serum lipid profiles in hypertensive patients

Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris

Magnetic and structural properties of rare earth transition metal carbides and nitrides

Postjunctional Selectivity of α-Blockade with Prazosin, Trimazosin, and UK-33,274 in Man

Profile of trimazosin: An effective and safe antihypertensive agent

Suchergebnisse filtern